Epigenetics: An emerging technology in the diagnosis and treatment of cancer

Pharmacogenomics

Volumn 7, Issue 5, 2006, Pages 747-757

  Stebbing, Justin ^a   Bower, Mark ^b   Syed, Nelofer ^c   Smith, Paul ^c   Yu, Veronica ^d   Crook, Tim ^c,e  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Epigenetics methylation; Tumor suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AZACITIDINE; BCR ABL PROTEIN; BRCA1 PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; DACOGENTRADE; DECITADINE; DNA; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; ESTROGEN RECEPTOR BETA; MASPIN; PACLITAXEL; POLO LIKE KINASE 2; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN P15; PROTEIN P53; PROTEIN P73; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; REELIN; RETINOIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR PITX2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; ZEBULARINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; CPG ISLAND; CYTOTOXICITY; DEMETHYLATION; DIAGNOSTIC PROCEDURE; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; ESOPHAGUS CANCER; FEVER; FREQUENCY ANALYSIS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; GLIOMA; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; IMMUNOPRECIPITATION; INFECTION; INJECTION SITE PAIN; LEUKOPENIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; MYELODYSPLASTIC SYNDROME; OCCULT BLOOD; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN MICROARRAY; REVIEW; THROMBOCYTOPENIA;

ANIMALS; EPIGENESIS, GENETIC; GENE THERAPY; HUMANS; NEOPLASMS;

EID: 33747133256     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.5.747     Document Type: Review

References (52)

1. Bhattacharya NP, Skandalis A, Ganesh A, Groden J, Meuth M: Mutator phenotype in human colorectal carcinoma cell lines. Proc. Natl Acad. Sci. USA 91, 6319-6323 (1994)
2. Yamashita K, Upadhyay S, Osada M et al.: Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495 (2002).
3. Ushijima T, Morimura K, Hosoya Y et al.: Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc. Natl Acad. Sci. USA 94, 2284-2289 (1997).
4. Rush LJ, Plass C: Restriction landmark genomic scanning for DNA methylation in cancer: past, present and future applications. Anal. Biochem. 307, 191-201 (2002).
5. Ballestar E, Paz MF, Valle L et al.: Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22, 6335-6345 (2003).
6. Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genet. 37, 853-862 (2005).
7. Wilson IM, Davies JJ, Weber M et al.: Epigenomics. Mapping the methylome. Cell Cycle 5, 155-158 (2006).
8. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
9. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A: Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Onc. 23, 7043-7049 (2005).
10. Bergamaschi D, Gasco M, Hiller L et al.: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).
11. Teodoridis JM, Strathdee G, Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Update 7, 267-278 (2004).
12. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10, 4420-4426 (2004).
13. Scolnick DM, Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406, 430-445 (2000).
14. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS: Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol®)-exposed cells. Mol. Cell Biol. 23, 5556-5571 (2003).
15. Syed N, Smith P, Sullivan A et al.: Transcriptional silencing of Polo-like kinase 2 (Snk/Plk2) is a frequent event in B-cell malignancies. Blood 107, 250-256 (2006).
16. Taniguchi T, Tischkowitz M, Ameziane N et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med. 9, 568-574 (2003).
17. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine in human colonic neoplasia. Cancer Res. 48, 1159-1161 (1988).
18. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al.: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/ antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24, 7213-7223 (2005).
19. Gore SD: Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nature Clin. Pract. Oncol. 2(Suppl. 1), S30-S35 (2005).
20. Baylin SB: DNA methylation and gene silencing in cancer. Nature Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005).
21. Fenaux P: Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nature Clin. Pract. Oncol. 2(Suppl. 1), S36-S44 (2005).
22. Novik KL, Nimmrich I, Genc B et al.: Epigenomics: genome-wide study of methylation phenomena. Curr. Issues Mol. Biol. 4, 111-128 (2002).
23. Economopoulos T, Stathakis N, Foudoulakis A et al.: Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur. J. Haematol. 38, 338-344 (1987).
24. Kerkhofs H, Hermans J, Haak HL, Leeksma CH: Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 65, 73-81 (1987).
25. Silverman LR, Demakos EP, Peterson BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440 (2002).
26. Kantarjian HM: Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J. Clin. Oncol. 20, 2415-2416 (2002).
27. Christman JK, Mendelsohn N, Herzog D, Schneiderman N: Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 43, 763-769 (1983).
28. Razin A, Riggs AD: DNA methylation and gene function. Science 210, 604-610 (1980).
29. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P: Promoter hypermethylation of p15, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur. J. Haematol. 76, 23-32 (2006).
30. Hackanson B, Guo Y, Lubbert M: The silence of the genes: epigenetic disturbances in hematopoietic malignancies. Expert Opin. Ther. Targets 9, 45-61 (2005).
31. Guo Y, Engelhardt M, Wider D, Abdelkarim M, Lubbert M: Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells. Leukemia 20, 115-121 (2005).
32. de Vos D: Epigenetic drugs: a longstanding story. Semin. Oncol. 32, 437-442 (2005).
33. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A: An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann. Hematol. 84(Suppl. 13), 9-17 (2005).
34. Balch C, Yan P, Craft T et al.: Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 4, 1505-1514 (2005).
35. Field JK, Liloglou T, Warrak S et al.: Methylation discriminators in NSCLC identified by a microarray based approach. Int. J. Oncol. 27, 105-111 (2005).
36. Scholz C, Nimmrich I, Burger M et al.: Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann. Hematol. 84, 236-244 (2005).
37. Guo J, Burger M, Nimmrich I et al.: Differential DNA methylation of gene promoters in small B-cell lymphomas. Am. J. Clin. Pathol. 124, 430-439 (2005).
38. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP: Methylation profiling in acute myeloid leukemia. Blood 97, 2823-2829 (2001).
39. Harbeck N, Bohlmann I, Ross JS, Maier S: Mutlicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated node negative breast cancer using paraffin-embedded tumor tissue. ASCO. Orlando, USA (2005).
40. Ferguson AT, Evron E, Umbricht CB et al.: High frequency of hypermethylation of 14-3-3σ locus leads to gene silencing in breast cancer. Proc. Natl Acad. Sci. USA 97, 6049-6054 (2000).
41. Gasco M, Bell AK, Heath V et al.: Epigenetic inactivation of 14-3-3σ in oral carcinoma: association with p16 (INK4a) silencing and human papillomavirus negativity. Cancer Res. 62, 2072-2076 (2002).
42. Agirre X, Roman-Gomez J, Jimenez-Velasco A et al.: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25, 1862-1870 (2006).
43. Corn PG, Kuerbitz SJ, van Noesel MM et al.: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59, 3352-3356 (1999).
44. Teodoridis JM, Hall J, Marsh S et al.: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65, 8961-8967 (2005).
45. Soengas MS, Capodieci P, Polsky D et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
46. Esteller M, Garcia-Foncillas J, Andion E et al.: Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
47. Esteller M, Gaidano G, Goodman SN et al.: Hypermethylation of the DNA repair gene O (6)-methylguanine DNA transferase and survival of patients with diffuse large B-cell lymphoma. J. Natl Cancer Inst. 94, 6-7 (2002).
48. Chang HG, Kim SJ, Chung KW et al.: Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene. J. Mol. Med. 83, 132-139 (2005).
49. Domann FE, Rice JC, Hendrix MJ, Futscher BW: Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 85, 805-810 (2000).
50. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275, 2727-2732 (2000).
51. Graff JR, Greenberg VE, Herman JG et al.: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res. 58, 2063-2066 (1998).
52. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M: Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 130, 548-565 (2006).